# US 2017/0281632 A1 · Methods of treating pediatric cancers

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0281632 A1
- Document ID: US20170281632A1
- Status: Published application
- Kind: A1
- Application number: 15/622,388
- Filed: 2017-06-14
- Published: 2017-10-05
- Earliest claimed: 2016-04-04
- Assignees: Loxo Oncology, Inc.
- Applicants: Loxo Oncology, Inc.
- Inventors: Michael Cox; Nisha Nanda
- Web page: https://patentgrep.com/patent/US20170281632A1

## CPC

- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 47/40: Cyclodextrins; Derivatives thereof
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method of treating a pediatric cancer in a subject in need thereof. The method includes administering to the subject a therapeutically effective amount of (S)—N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide, or a pharmaceutically acceptable salt thereof, or a combination thereof.

## Claims

### Claim 1

A method of treating a pediatric cancer in a subject in need thereof, wherein the cancer is selected from the group comprising congenital mesoblastic nephroma, Ph-like acute lymphoblastic leukemia, infantile fibrosarcoma, pediatric high-grade glioma (HGG), diffuse intrinsic pontine gliomas (DIPGs), pediatric papillary thyroid carcinoma, soft tissue sarcoma, and spindle cell sarcoma, the method comprising administering to the subject a therapeutically effective amount of (S)—N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide having the formula (I):
a pharmaceutically acceptable salt thereof, or combinations thereof.

### Claim 2 (depends on 1)

The method of claim 1, wherein the subject is an infant.

### Claim 3 (depends on 1)

The method of claim 1, wherein the cancer is mediated by TrkA, TrkB, TrkC, or combinations thereof.

### Claim 4 (depends on 1)

The method of claim 1, wherein the pediatric cancer is infantile fibrosarcoma.

### Claim 5 (depends on 4)

The method of claim 4, wherein surgical resection has failed to inhibit progression of the fibrosarcoma in the subject.

### Claim 6 (depends on 1)

The method of claim 1, wherein chemotherapy previously failed to inhibit tumor progression in the subject.

### Claim 7 (depends on 1)

The method of claim 1, further comprising performing one or more of morphological diagnosis and molecular testing prior to administering the compound of formula (I), a pharmaceutically acceptable salt thereof, or a combination thereof.

### Claim 8 (depends on 1)

The method of claim 1, wherein the compound of formula (I) is a hydrogen sulfate salt.

### Claim 9 (depends on 1)

The method of claim 1, wherein the compound of formula (I) is provided as a crystalline form.

### Claim 10 (depends on 1)

The method of claim 1, wherein the compound of formula (I), a pharmaceutically acceptable salt thereof, or a combination thereof, is provided as a liquid formulation.

### Claim 11 (depends on 10)

The method of claim 10, wherein the liquid formulation further comprises:
a solubilizing agent, wherein the solubilizing agent comprises a 3-cyclodextrin; and
a base;
wherein:
the formulation has a pH of about 2.5 to about 5.5; and
the compound of formula (I) has a concentration of about 15 mg/mL to about 35 mg/mL in the liquid formulation.

### Claim 12 (depends on 11)

The method of claim 11, wherein the formulation has a pH of about 3 to about 4.

### Claim 13 (depends on 11)

The method of claim 11, wherein the β-cyclodextrin is hydroxypropyl-β-cyclodextrin.

### Claim 14 (depends on 11)

The method of claim 11, wherein the base is a citrate.

### Claim 15 (depends on 14)

The method of claim 14, wherein the base comprises sodium citrate dihydrate.

### Claim 16 (depends on 10)

The method of claim 10, wherein the liquid formulation further comprises:
a solubilizing agent, wherein the solubilizing agent comprises a β-cyclodextrin;
a base;
a sweetener;
a bitterness masking agent; and
a flavoring agent,
wherein:
the formulation has a pH of about 2.5 to about 5.5; and
the compound of formula (I) has a concentration of about 15 mg/mL to about 35 mg/mL in the liquid formulation.

### Claim 17 (depends on 10)

The method of claim 10, wherein the liquid formulation is prepared from a crystalline form of the compound of formula (I) having the formula (I-HS):

### Claim 18 (depends on 17)

The method of claim 17, wherein the crystalline form is characterized by having XRPD diffraction peaks (2θ degrees) at 18.4±0.2, 20.7±0.2, 23.1±0.2, and 24.0±0.2.

### Claim 19 (depends on 17)

The method of claim 17, wherein the crystalline form is characterized by having XRPD diffraction peaks (2θ degrees) at 10.7±0.2, 18.4±0.2, 20.7±0.2, 23.1±0.2, and 24.0±0.2.

### Claim 20 (depends on 17)

The method of claim 17, wherein the crystalline form is characterized by having XRPD diffraction peaks (2θ degrees) at 10.7±0.2, 18.4±0.2, 19.2±0.2, 20.2±0.2, 20.7±0.2, 21.5±0.2, 23.1±0.2, and 24.0±0.2.

### Claim 21 (depends on 17)

The method of claim 17, wherein the crystalline form is characterized by having XRPD diffraction peaks (2θ degrees) at 10.7±0.2, 15.3±0.2, 16.5±0.2, 18.4±0.2, 19.2±0.2, 19.9±0.2, 20.2±0.2, 20.7±0.2, 21.5±0.2, 22.1±0.2, 23.1±0.2, 24.0±0.2, 24.4±0.2, 25.6±0.2, 26.5±0.2, 27.6±0.2, 28.2±0.2, 28.7±0.2, 30.8±0.2, and 38.5±0.2.

### Claim 22 (depends on 1)

The method of claim 1, wherein the compound of formula (I), a pharmaceutically acceptable salt thereof, or a combination thereof, is administered in 28-day cycles.

### Claim 23 (depends on 1)

The method of claim 1, wherein the compound is administered in a dosage calculated to be the equal to the exposure of an adult taking the compound of formula (I), a pharmaceutically acceptable salt thereof, or a combination thereof, at a dose of 100 mg twice a day.

### Claim 24 (depends on 1)

The method of claim 1, wherein the pediatric cancer is associated with or having a dysregulation of a NTRK gene, a Trk protein, or expression or activity, or level of the same.

### Claim 25 (depends on 24)

The method of claim 24, wherein the dysregulation of a NTRK gene, a Trk protein, or expression or level of the same is a chromosome translation that results in the translation of a Trk fusion protein.

### Claim 26 (depends on 25)

The method of claim 25, wherein the Trk fusion protein is selected from the group consisting of ETV6-NTRK3, RET/NTRK1, TPM3-NTRK1, BTBD1-NTRK3, VCL-NTRK2, AGBL4-NTRK2, LMNA-NTRK1, TFG-NTRK1, QKI-NTRK2, NACC2-NTRK2, TPR-NTRK 1, RABGAP1L-NTRK1, MPRIP-NTRK1, SQSTM1-NTRK1, EML4-NTRK3, and AFAP1-NTRK2.

### Claim 27 (depends on 26)

The method of claim 26, wherein the Trk fusion protein is ETV6-NTRK3.

### Claim 28 (depends on 24)

The method of claim 24, wherein the dyregulation of a NTRK gene, a Trk protein, or expression or activity of the same is one or more point mutations in the gene.

### Claim 29 (depends on 28)

The method of claim 28, wherein the one or more point mutations in the gene is one or more of (i) a TrkA point mutation selected from the group consisting of C6773T, C7232T, C7301T, R33W, A336E, A337T, R324Q, R324W, V420M, R444Q, R444W, G517R, G517V, K538A, V573M, F589L, G595R, G667C, F598L, R649W, R649L, R682S, V683G, R702C, Q627X, Q597X, and Q633X; (ii) a TrkB point mutation selected from the group consisting of A13T, E142K, R136H, V619M, F633L, G639R, G709C, G709A, and G709S; and/or (iii) a TrkC point mutation selected from the group consisting of V603M, F617L, G623R, G696C, G696A, and G696S.
